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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurologic disease characterized by progressive motor neuron degeneration.
Clinical disease management is hindered by both a lengthy diagnostic process and the absence of effective treatments.
Reliable panels of diagnostic, surrogate, and prognostic biomarkers are needed to accelerate disease diagnosis and expedite
drug development. The cysteine protease inhibitor cystatin C has recently gained interest as a candidate diagnostic
biomarker for ALS, but further studies are required to fully characterize its biomarker utility. We used quantitative enzyme-
linked immunosorbent assay (ELISA) to assess initial and longitudinal cerebrospinal fluid (CSF) and plasma cystatin C levels
in 104 ALS patients and controls. Cystatin C levels in ALS patients were significantly elevated in plasma and reduced in CSF
compared to healthy controls, but did not differ significantly from neurologic disease controls. In addition, the direction of
longitudinal change in CSF cystatin C levels correlated to the rate of ALS disease progression, and initial CSF cystatin C levels
were predictive of patient survival, suggesting that cystatin C may function as a surrogate marker of disease progression
and survival. These data verify prior results for reduced cystatin C levels in the CSF of ALS patients, identify increased
cystatin C levels in the plasma of ALS patients, and reveal correlations between CSF cystatin C levels to both ALS disease
progression and patient survival.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular
disease that affects approximately 1.5 to 2.5 per 100,000
individuals of all races and ethnicities throughout the world [1].
ALS patients typically undergo rapid disease progression, though a
subset exhibits slow progression and may live over a decade from
symptom onset [2,3]. Unfortunately, there is only one drug
currently approved by the FDA to treat ALS, and this therapy
increases life span by just two to three months on average [4].
Clinical disease management is also hindered by an often lengthy
diagnostic process based predominately on clinical criteria [5]. As
new drugs that slow or arrest disease progression become
available, early initiation of treatment will become paramount.
For this reason, diagnostic biomarkers for ALS must be identified
and validated to maximize treatment efficacy for future patients.
Several individual panels of CSF proteins have shown promise as
candidate biomarkers, but none have been fully validated or
integrated into clinical practice [6,7,8].
Biomarkers also hold promise to monitor disease progression
and to stratify patient populations for use in clinical trials. One
reason new drug therapies have not been successfully translated
from ALS model systems to humans is ALS disease heterogeneity
[9]. Biomarkers that monitor disease progression would aid in the
design and execution of human clinical trials and would provide
novel targets for future drug therapies; prognostic biomarkers that
predict patient survival would also aid in the design of clinical
trials. While there are several validated demographic and clinical
prognostic factors for ALS, disease prognosis cannot currently be
predicted with high accuracy within individual patients [10].
Ultimately, surrogate biomarkers of disease progression would
provide a means to more rapidly monitor drug efficacy in clinical
trials [5,9,11,12]. Therefore, the search for biomarkers that fit
these functional characteristics represents a key challenge toward
improving drug therapies and clinical management for ALS.
One protein that has shown potential for ALS diagnostic utility
is cystatin C, a widely expressed cysteine protease inhibitor that is
approximately five times more abundant in CSF than in plasma
[13]. Cystatin C is processed through the secretory pathway, and,
in its active monomeric form, inhibits a wide variety of cysteine
proteases including cathepsins B, H, L, and S, calpains and
caspases [14]. Cystatin C is also linked to ALS histopathologically,
as it is one of only two known proteins that localize to Bunina
bodies, which are small intraneuronal inclusions specific to ALS
[15].
Two prior surface-enhanced laser desorption/ionization time of
flight mass spectrometry (SELDI-TOF-MS) studies reported
significant decreases in CSF cystatin C levels in ALS patients
relative to healthy controls [6] and mixed healthy/neurologic
disease controls [7]. A recent study using small numbers of test
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subjects reported a significant reduction in CSF cystatin C
concentration in ALS patients relative to individuals with
polyneuropathy, as measured by ELISA [16]. While these prior
studies are encouraging, a larger study with a more comprehensive
group of ALS-mimic disease controls is required in order to verify
prior results and determine if CSF cystatin C levels represent a
candidate diagnostic biomarker for ALS.
The objective of this study was to use quantitative ELISA to
further evaluate the utility of cystatin C as a biomarker for ALS
using a large subject population. Our subject group size was based
on power analysis of previously published mass spectrometry
reports on cystatin C in ALS [6,7]. We evaluated cystatin C in
both CSF and plasma as a candidate diagnostic biomarker, and
correlated levels to individual ALS patient survival and disease
progression. We verified that cystatin C protein levels are reduced
in the CSF of ALS patients and discovered that cystatin C levels
are increased in the plasma of ALS patients. However, cystatin C
levels in either biofluid were not highly predictive of ALS. We also
determined that CSF cystatin C levels correlate to ALS patient
survival, and change during disease progression.
Results
We collected longitudinal CSF and plasma samples from 104
ALS and control subjects (Table 1) and evaluated the absolute
cystatin C concentrations by ELISA and the total sample protein
concentrations by BCA protein assay. We then assessed the
biomarker utility of two separate measures of cystatin C: (1) the
absolute cystatin C concentrations or ‘‘total cystatin C’’ and (2) the
‘‘percent cystatin C,’’ in which the absolute cystatin C concentra-
tions were normalized to the total sample protein concentrations
to determine the percent of total biofluid protein accounted for by
cystatin C. We also collected several clinical measures of disease
progression at the time of each biofluid draw (see methods).
Diagnostic biomarker assessment
In order to assess the diagnostic utility of cystatin C, we first
compared the mean first-draw cystatin C levels among ALS
patients, neurologic disease controls, and healthy controls. A
generalized linear model was used to estimate the mean total and
percent cystatin C for each diagnostic category, with both gender
and age included as co-factors in the model. This statistical design
controls for between-group differences in each co-factor when
generating estimated means. Therefore, the differences in age and
gender among our diagnostic groups should not have affected our
results, even in the case that cystatin C varies with these factors.
We found that the estimated means for both measures of cystatin
C were lower in ALS patients than in disease controls and healthy
controls, similar to prior studies (Table 2). However, a test of the
model’s main effects revealed that only percent cystatin C differed
significantly by disease diagnosis, while total cystatin C levels were
not significantly different across diagnostic groups. Neither
measure of cystatin C differed significantly by age or gender. In
a post-hoc pairwise comparison of diagnostic groups, percent
cystatin C was found to be significantly lower in CSF of both ALS
patients and disease controls relative to healthy controls, but there
was no statistical difference between cystatin C levels in ALS
patients and disease controls.
Next, we repeated these statistical analyses using data from
specific patient subgroups, in order to determine if either measure
of CSF cystatin C can be used to differentiate ALS patients from
disease controls in specific patient subpopulations. First, we
created a subcategory of disease controls comprised of patients
with neurologic diseases that more closely resemble ALS at
presentation. Using this group of ALS mimics in our statistical
model, the patterns of overall and between-group statistical
differences remained the same (data not shown). However, the
p-values were reduced for the ALS vs. mimic disease control
subgroup comparison (Table 3, first row) relative to the ALS vs. all
disease control subgroup comparison (Table 2, ‘‘ALS vs. DC’’)
suggesting a stronger trend toward statistical significance when
Table 1. Clinical characteristics of all study participants.
ALS (n =44)
All Disease Controls
(n =25)
Mimic Disease Controls
(n =9)
Healthy controls
(n =35)
Sex (male/female) 31/13 13/12 7/2 13/22
Age at first draw ± SD (years) 54.8613.5 47.9615.4 57.2611.8 46.8615.6
Relevant subgroups 35 limb onset, 5 bulbar
onset, 4 mixed/other onset
9 ALS mimics, 6 MS,
10 other
2 PLS, 2 CIDP, 2 PMA, 1 SA, 1 small fiber
neuropathy, 1 idiopathic sensorimotor
polyneuropathy
NA
MS = multiple sclerosis; PLS = primary lateral sclerosis; CIDP = chronic inflammatory demyelinating polyneuropathy; PMA = progressive muscular atrophy; SA =
spinocerebellar ataxia; NA = not applicable.
doi:10.1371/journal.pone.0015133.t001
Table 2. CSF main group results for total and percent cystatin
C.
Total Cystatin C Percent Cystatin C
Mean (ug/ml) ± S.E.M. Mean (%)± S.E.M.
ALS (n =44) 3.326.19 0.4060.02
DC (n=25) 3.616.26 0.4560.03
HC (n=35) 4.006.25 0.5460.03
Significance of Model Main Effects (p-values)
Diagnosis 0.109 0.002*
Gender 0.400 0.740
Age at Draw 0.367 0.672
Pairwise Comparisons by Diagnosis (p-values)
ALS vs. DC 0.384 0.259
ALS vs. HC 0.038* 0.001*
DC vs. HC 0.277 0.034*
Percent cystatin C differed significantly by diagnostic category and was
significantly reduced in both ALS patients and disease controls relative to
healthy controls. ALS = all ALS patients; DC = all neurologic disease controls;
HC = healthy controls. Asterisks indicate statistical significance at p,0.05.
doi:10.1371/journal.pone.0015133.t002
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cystatin C is used to differentiate ALS patients from this more
clinically-relevant control group.
We next compared two ALS subgroups to the disease mimic
group. Limb-onset ALS (ALS-L) and ALS patients greater than
one year from symptom onset both exhibited reduced levels of
cystatin C in the CSF when compared to disease mimics (Table 3),
with improved p-values when compared to the analysis including
all ALS patients. However, the pair-wise comparisons between
these ALS subgroups and mimic disease controls still fell short of
statistical significance.
Finally, we calculated the diagnostic sensitivity and specificity
for several cutoff concentration values of CSF cystatin C. Total
cystatin C concentration measurements were found to have better
diagnostic parameters than percent cystatin C values. A cutoff
value of 2.20 mg/ml identified a small subset of ALS patients
(sensitivity: 23%) with relatively high specificity (88% vs. all study
controls, 100% vs. mimic disease controls). A cutoff value of
2.70 mg/ml identified a modest subset of ALS patients (sensitivity:
32%) while maintaining high specificity versus controls (specificity:
78% vs. all study controls, 100% vs. mimic disease controls). A less
conservative cutoff value of 3.50 mg/ml identified a majority of
ALS patients (sensitivity: 52%), but demonstrated lower specificity
(specificity: 52% vs. all study controls, 89% vs. mimic disease
controls).
As noted above, cystatin C was previously reported to be
significantly reduced in the CSF of ALS patients using mass
spectrometry-based proteomics, but the between-group differences
based on our ELISA data were less robust. To explore the
relationship between CSF cystatin C levels measured by these two
techniques, we compared our ELISA results with SELDI-TOF-
MS data for the same CSF samples. We found significant, positive
correlations between the 13.3 kDa SELDI-TOF-MS mass peak
intensity for cystatin C and both total cystatin C and percent
cystatin C protein levels as measured by ELISA (p = 0.002 and
p,0.001, respectively; Figure S1). However, the correlation
coefficients (Spearman r= 0.443 and 0.595, respectively) suggest
that these techniques may be differentially sensitive to various
modified forms of native cystatin C.
We repeated the group analysis for the diagnostic utility of
cystatin C in plasma, and both measures of cystatin C varied
significantly by diagnosis and age, but not by gender (Table 4).
Post-hoc analyses revealed that total and percent cystatin C were
significantly increased in both ALS patients and disease controls
relative to healthy controls. However, there were no differences in
cystatin C levels between ALS patients and disease controls.
Identical trends were observed for all subgroup analyses of cystatin
C levels in plasma (data not shown).
To further characterize the relationship between CSF and
plasma cystatin C levels, we assessed the correlation between CSF
and plasma cystatin C levels for individual subjects. The results
indicated that there is no correlation between total cystatin C
concentrations (Spearman r= 0.055; p = 0.626) or percent cystatin
C levels (Spearman r=20.076; p = 0.501) in CSF and plasma
samples drawn from individual patients on the same day (Figure
S2). The absence of a relationship between CSF and plasma
cystatin C levels suggests that this protein is independently
regulated in both biofluid pools, and that plasma cystatin C is
unlikely to be directly influenced by CSF levels.
Cystatin C as a biomarker for disease progression
We next examined whether cystatin C levels change over time
in ALS patients, and if these changes are associated with clinical
disease progression. We compiled the first CSF draws for each of
the ALS patients in our study and carried out linear regressions
comparing both total and percent cystatin C with the time from
symptom onset. Similar to a prior study [16], we found no
statistically significant linear relationship between these variables
in our data set (Figure 1). However, we did observe a slight trend
toward a reduction in cystatin C levels over time from symptom
onset, particularly for percent cystatin C (Figure 1B).
Next, we collected longitudinal CSF samples from ALS patients
and assessed the effect of time on cystatin C levels using a statistical
model for repeated measures. This experimental design controls
Table 3. CSF subgroup results for total and percent cystatin C.
N
Mean Total Cystatin
C (ug/ml) ± S.E.M.
Significance of Pairwise
Difference (p-values)
Mean Perecent
Cystatin C ± S.E.M.
Significance of Pairwise
Difference (p-values)
ALS vs mimic DC 44/9 3.3560.19 vs 3.9960.48 0.212 0.4060.02 vs 0.4960.06 0.129
ALS-L vs mimic DC 35/9 3.336.021 vs 4.0060.49 0.196 0.4060.02 vs 0.4960.06 0.098
ALS.1yr vs mimic DC 29/9 3.2460.22 vs 3.9960.48 0.151 0.3960.03 vs 0.4960.06 0.093
The diagnostic potential of both measures of cystatin C, as implied by the pair-wise difference p-values, was improved when comparing ALS to mimic DC rather than all
DC (top row vs. Table 2). Additionally, the diagnostic potential vs. mimic DC was higher for two ALS subgroups, ALS-L and ALS.1yr, than for all ALS patients combined.
ALS-L = limb-onset ALS; ALS.1yr = patients with first biofluid draw occurring more than one year following symptom onset.
doi:10.1371/journal.pone.0015133.t003
Table 4. Plasma main group results for total and percent
cystatin C.
Total Cystatin C Perecent Cystatin C
Mean (ug/ml) ± S.E.M. Mean (%)± S.E.M.
ALS (n =43) 0.81860.024 1.066102363.3661025
DC (n=11) 0.86160.048 1.126102366.7861025
HC (n=31) 0.70560.023 0.896102363.1761025
Significance of Model Main Effects (p-values)
Diagnosis 0.001* ,0.001*
Gender 0.457 0.293
Age at Draw 0.004* 0.003*
Pairwise Comparisons by Diagnosis (p-values)
ALS vs. DC 0.442 0.419
ALS vs. HC 0.001* ,0.001*
DC vs. HC 0.004* 0.002*
Both measures of cystatin C differed significantly by age at draw and by
diagnostic category. Cystatin C levels were significantly elevated in ALS patients
and disease controls relative to healthy controls but there were no differences
in cystatin C levels between ALS patients and disease controls. Asterisks
indicate statistical significance at p,0.05.
doi:10.1371/journal.pone.0015133.t004
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for individual differences in baseline cystatin C levels, but not for
individual differences in rate of disease progression. We collected
at least three longitudinal CSF draws from 15 ALS patients over a
1–2 year time period for each patient. When all 15 values were
averaged for each time point, we did not observe a significant
change in cystatin C levels over time (Table 5, ‘‘All Patients’’).
To control for individual differences in disease progression
speed, we separated ALS patients into two groups: fast progressors,
who demonstrated a rapid clinical decline during the study period,
and slow progressors, whose clinical decline was slower than
average (see methods section). When the rate of disease
progression was included as a factor in the statistical model, we
found a significant interaction between the effects of time and
progression speed for total cystatin C measurements (Table 5,
Time*Progression Speed column), indicating that longitudinal
changes in cystatin C concentration follow different patterns in the
two patient subpopulations. In order to determine the direction
and significance level of the longitudinal subgroup changes
responsible for this interaction, we applied the repeated measures
test individually to each patient subgroup. Fast progressors
exhibited a subtle, non-significant decrease in cystatin C levels
over time. In contrast, slow progressors exhibited a trend of
increasing cystatin C levels over time (p = 0.058, Table 5), which
likely accounts for the majority of the time/progression speed
interaction. Similar trends were observed for percent cystatin C
measurements. For comparison, we also assessed the longitudinal
change in CSF cystatin C levels in 10 healthy controls, each with
two CSF samples drawn 1.5–2 years apart. A repeated measures t-
test revealed a modest increase in total cystatin C concentration
over time in these healthy controls but no longitudinal change in
percent cystatin C levels (data not shown).
Correlation of cystatin C to survival
Finally, we assessed the relationship between first-draw cystatin
C levels (in CSF and plasma) and patient survival time. Neither
measure of plasma cystatin C showed a correlation with
subsequent survival time (total cystatin C: Spearman r=20.17,
p=0.537), but both measures of CSF cystatin C levels showed a
direct correlation, with the results for total cystatin C almost
reaching statistical significance (total cystatin C: Spearman
r= 0.465, p=0.052). These findings suggest that cystatin C levels
in CSF but not plasma may be useful as prognostic indicators of
patient survival time.
We further explored this correlation by generating Kaplan-Meier
survival curves for total CSF cystatin C measurements. For these
analyses, patients were sorted into high- and low-cystatin C groups
according to their first-draw cystatin C levels. Qualitative data
assessment revealed that short survival times were most strongly
associated with the lowest cystatin C levels and, for this reason, we
selected a cut-off value of 2.75 mg/ml to separate the ALS patients
Figure 1. Linear regressions for CSF cystatin C levels vs. time from symptom onset. The slope of the best-fit lines (solid) for both total (A)
and percent (B) cystatin C did not significantly differ from zero (p=0.368 and p=0.193, respectively). Dashed line = 95% confidence interval for best-
fit line.
doi:10.1371/journal.pone.0015133.g001
Table 5. Repeated measures tests for the change in total cystatin C concentration over time.
Total Cystatin
C (mg/ml)
Draw 1
Mean ± S.E.M.
Draw 2
Mean ± S.E.M.
Draw 3
Mean ± S.E.M.
Trend Over
Time
Change Over
Time (p-values)
Time*Progression
Speed (p-values)
All Patients (n =15) 3.5460.27 3.6460.28 3.6260.29 flat 0.663 N/A
Fast Progressors (n=6) 4.1160.30 4.0260.34 3.8260.36 Q 0.333 0.032*
Slow Progressors (n =9) 3.1760.20 3.3960.23 3.4960.26 qq 0.058
There were no significant longitudinal changes in CSF cystatin C concentration in ALS patients as a combined group, but fast progressors showed a moderate
longitudinal decrease and slow progressors showed a moderate longitudinal increase. There was a significant interaction between the change in cystatin C
concentration over time and patient progression speed (fast versus slow progressors) as listed in Time.
*Progression speed column (p= 0.032). Asterisk indicates statistical significance at p,0.05.
doi:10.1371/journal.pone.0015133.t005
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into a smaller low cystatin C group (n=11) and a larger high cystatin
C group (n=21). This analysis revealed significantly longer patient
survival in the high cystatin C group than in the low cystatin C group
(Figure 2A). Next, because the ALS disease course and average
survival time differ significantly between limb-onset ALS and bulbar-
onset ALS, we repeated these statistical tests with exclusively limb-
onset patients. Within this population, the between-group difference
in post-draw survival time became even more striking (Figure 2B),
further reinforcing our finding that ALS patients with low CSF
cystatin C levels exhibit reduced survival times relative to patients
with average to high CSF cystatin C levels. Similar results were
obtained using percent cystatin C measurements.
Figure 2. Kaplan-Meier survival curves. For all ALS patients (A), survival was significantly longer (p,0.014) in patients with high cystatin C levels
(n = 21) than in patients with low cystatin C levels (n = 11). For patients with limb onset ALS (B), the same trend was observed, but with a larger
survival difference (p,0.010) between patients with high (n = 13) and low (n= 10) cystatin C levels.
doi:10.1371/journal.pone.0015133.g002
Cystatin C as an ALS Biomarker
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Discussion
The present study represents a comprehensive evaluation of
cystatin C as a candidate biomarker in ALS, and is unique in its
assessment of two distinct biofluids (CSF and blood plasma), two
different measurements of the protein of interest (total concentra-
tion and percent of total protein), and longitudinally collected CSF
samples. Prior studies using SELDI-TOF-MS found significantly
lower cystatin C abundance in the CSF of ALS patients relative to
healthy controls [6] and mixed healthy/neurologic disease controls
[7]. These findings were validated by ELISA and immunoblot,
respectively. In our current ELISA study for diagnostic utility
using a much larger number of total subjects, we also found a
significant reduction in cystatin C levels in the CSF of ALS
patients relative to healthy controls, but the magnitude of this
difference was less robust than in the previous reports. This
discrepancy may have resulted from the use of different
experimental techniques, as SELDI-TOF-MS recognizes discrete
mass-to-charge forms of cystatin C, whereas ELISA may recognize
multiple modified or cleaved forms of cystatin C depending upon
the antibodies used for capture and detection. Regarding the
comparison of these two techniques, we found a significant,
positive correlation but a low correlation coefficient between our
CSF ELISA data and SELDI-TOF-MS data for the same samples
(Figure S1). This finding suggests that these techniques are
sensitive to different, but possibly overlapping, ranges of native
cystatin C isoforms, and may provide differential, and perhaps
complementary, utility in detecting cystatin C for biomarker
assessment.
To be clinically useful as a diagnostic biomarker, cystatin C
must also be able to differentiate between ALS patients and
individuals with neurologic diseases that closely resemble ALS, or
ALS ‘‘mimic diseases.’’ A recent study reported a significant
reduction in CSF cystatin C levels in ALS patients relative to
polyneuropathy patients [16]. In our ELISA analysis, cystatin C
was reduced in the CSF of ALS patients relative to all DC
combined and, to a greater degree, relative to a mimic disease
control group that included a variety of ALS mimics (Table 3), but
neither difference reached statistical significance. Because these
between-group differences were smaller than we expected based
on previous mass spectrometry data [17], we conducted a new
power analysis using our experimentally-derived group means and
standard deviations. This analysis revealed that our study was
adequately powered for comparing percent cystatin C between
ALS and HC (a significant difference was found), and underpow-
ered for comparing total cystatin C between ALS and HC (main
group effects missed significance, but the pairwise comparison was
significant), and for comparing ALS with DC for both measures of
cystatin C (no significant differences were identified). The observed
reductions in both total and percent cystatin C in ALS patients
relative to DC may reflect actual differences in clinical cystatin C
levels, but a total study enrollment of 1020 and 675 patients (for
total and percent cystatin C, respectively) would be required to
confirm statistical significance with 80% power and 95%
confidence. Interestingly, the between-group differences and trend
towards significance improved when comparing limb-onset ALS
patients or ALS patients with disease course greater than 1 year
from symptom onset to the ALS mimics (Table 3). Additionally,
we found that the total cystatin C concentration measurement
generated superior diagnostic accuracy, indicating that this may be
the more efficacious measure of cystatin C. An assessment of the
diagnostic parameters of CSF cystatin C concentration revealed
that the sensitivity of cystatin C for differentiating ALS patients
from disease controls is low for all cutoff values but it displays high
levels of specificity and, therefore, cystatin C can only identify a
small subset of ALS patients. Together, these findings indicate that
CSF cystatin C levels may differ between ALS patients and
relevant disease control populations but cystatin C, by itself, has
limited diagnostic utility. However, this protein could potentially
improve the sensitivity and/or specificity of a diagnostic biomarker
panel. Due to the heterogeneous nature of the ALS patient
population, it is likely that a multiple biomarker panel will be
required, as opposed to any single protein biomarker, in order to
differentiate ALS from related disorders with adequate diagnostic
certainty [18].
We also assessed the diagnostic utility of plasma cystatin C
levels. Plasma cystatin C has been extensively characterized as a
peripheral biomarker for kidney function and as a prognostic
indicator of the risk of morbidity and mortality relating to
cardiovascular disease [19,20]. However, blood-borne levels of
cystatin C have not been evaluated as a biomarker candidate for
neurologic disorders. We found that plasma cystatin C levels are
equivalently elevated in both ALS patients and disease controls
relative to healthy controls, indicating that elevated plasma
cystatin C is a nonspecific finding associated with neurologic
disease states. Therefore, plasma cystatin C levels, as evaluated by
ELISA, do not to have diagnostic utility for ALS. Furthermore, the
absence of a relationship between cystatin C levels in concurrently-
drawn CSF and plasma samples from individual patients in this
study (Figure S2) suggests that this protein is independently
regulated in each biofluid. Accordingly, plasma cystatin C levels
are unlikely to be directly correlated with motor neuron
degeneration in ALS, though elevated levels may correlate to
peripheral metabolic or inflammatory abnormalities during ALS.
A recent study examined a single CSF draw per ALS patient,
taken at varying times from symptom onset, to indirectly infer the
average longitudinal change in cystatin C concentration in the
group as a whole, and they reported that cystatin C levels do not
change over time [16]. We completed a similar analysis and also
found no evidence for a patterned directional change in CSF
cystatin C levels over time in ALS patients (Figure 1). However,
both heterogeneity in disease progression speed and individual
variation in baseline cystatin C levels could mask significant trends
in cystatin C change over the course of disease progression and,
therefore, single-draw protein levels are unsuitable for a thorough
assessment of longitudinal trends in cystatin C abundance.
We also examined longitudinal CSF data from multiple patients
to more accurately assess the changes in cystatin C over time. We
found that longitudinal cystatin C concentrations were relatively
constant in ALS patients as a combined group. In contrast, the
subgroup of patients with slow or absent clinical disease
progression exhibited longitudinal increases in cystatin C concen-
tration, and the subgroup with more typical, continuous clinical
deterioration exhibited longitudinal decreases in total cystatin C.
Interestingly, slow progressors often exhibited lower initial levels of
CSF cystatin C than fast progressors (Table 5). Similar trends were
also observed for percent cystatin C measurements, but statistical
significance was not reached. These results indicate that CSF
cystatin C levels in ALS patients change over time in a clinically-
relevant manner and that increasing cystatin C concentration may
be associated with slower disease progression. Conversely, rapid
disease progression may be associated with a decrease in cystatin C
concentration over time.
We also conducted an analysis to determine the relationship
between longitudinal changes in CSF cystatin C levels and time-
matched changes in three functional clinical measures of disease
progression (ALSFRS-R, MMT, and FVC). However, no
significant correlations were found (data not shown). This indicates
Cystatin C as an ALS Biomarker
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that cystatin C levels may change independently of the clinical
parameters used for monitoring disease progression. However, this
finding does not eliminate the possibility that changes in CSF
cystatin C levels correlate with more subtle biochemical changes
associated with disease progression, as these may not be accurately
reflected by overt functional measures of clinical disease status
[9,11]. Furthermore, the observed trend of increasing cystatin C
levels in patients with slow rates of clinical deterioration may prove
to be useful as an objective biomarker for monitoring drug effects
in clinical trials.
We recently demonstrated a correlation between CSF cystatin
C levels and patient survival by SELDI-TOF-MS [17]. In this
study, we further verified a direct correlation between CSF
cystatin C concentration and patient survival time, supporting the
potential utility of this protein for prognostic applications.
Subsequent Kaplan-Meier survival analyses for patient groups
with CSF cystatin C concentrations above and below qualitatively
selected cut-off values confirmed significantly longer survival times
for patients in the higher cystatin C groups. Additionally, the
prognostic capacity of CSF cystatin C was higher for limb-onset
patients (Figure 2B) than for all patients combined (Figure 2A).
This may have resulted from the confounding effects of combining
patients with different sites of disease onset, as bulbar-onset ALS
patients typically have shorter survival times than limb-onset
patients [2,3]. Unfortunately, there were inadequate numbers of
bulbar-, trunk-, and/or dementia-onset patients to analyze these
individual subgroups in this study, and further analyses are
required to determine the prognostic capacity of cystatin C in
these subgroups. Nonetheless, these results show that cystatin C is
a candidate prognostic indicator of survival in ALS patients.
Alternatively, cystatin C levels could contribute to the process of
balancing prognostic variables among experimental groups as
recommended to equalize drop-out rates and preserve the
balancing effects of randomization in clinical trials [9]. Further
work is required to more fully characterize the relationship
between CSF cystatin C concentration and ALS patient survival,
and to determine optimal cut-off values and procedures to stratify
patients for prognostic purposes.
The results of this comprehensive biomarker assessment also
have implications for the potential mechanistic involvement of
cystatin C in the pathogenesis of ALS. The function of cystatin C
within the CNS has not been extensively studied, but it appears to
have both neurotoxic and neuroprotective properties [21,22,
23,24], though its effects specifically on motor neurons have not
been reported. The majority of cystatin C in the CSF is produced
by the choroid plexus [25], but it is unclear whether the apparent
reductions in CSF levels in ALS patients are an independent
etiological factor contributing to motor neuron degeneration, a
downstream result of disease pathogenesis, or a compensatory
response to ALS pathology. However, the association of higher
cystatin C concentrations with longer patient survival and the
association of increasing cystatin C levels with slower clinical
progression both suggest that extracellular cystatin C may exhibit
neuroprotective properties within the context of ALS. This would
implicate any absolute or relative cystatin C deficiency in ALS as
both a potential contributor to disease pathogenesis and a
potential therapeutic target. Continuing work in our laboratory
is focused on determining the effects of altered cystatin C
concentration/activity on motor neurons in vitro, in order to
clarify its potential mechanistic role in ALS pathogenesis.
In summary, we have completed a comprehensive evaluation of
cystatin C as a candidate ALS biomarker, including assessments of
two complementary measures of cystatin C in two distinct biofluids
as well as examinations of both longitudinal CSF samples and
patient survival data. Our findings indicate that cystatin C levels,
as determined by ELISA, are increased in the plasma and
decreased in the CSF of ALS patients relative to healthy controls.
CSF cystatin C measurements may possess a more limited
diagnostic capacity for ALS than previously proposed, but may
still have the potential to improve the diagnostic parameters of a
biomarker panel. Additionally, longitudinal changes in CSF
cystatin C levels may be useful as a biomarker of fast versus slow
rates of disease progression. Our data also demonstrate that CSF
cystatin C concentration has prognostic utility in estimating
patient survival time. Further validation studies are necessary to
confirm these findings and ultimately determine if cystatin C
measurements can be used to enhance clinical disease manage-
ment and clinical trial design. Finally, the association of high or
increasing cystatin C levels with slower disease progression and
increased survival time suggests a potential neuroprotective role
for this protein in the pathobiology of ALS.
Materials and Methods
Sample Collection and Ethics Statement
This study was approved by the institutional review board (IRB)
at the University of Pittsburgh, and written informed consent was
obtained from all participating subjects. ALS subjects were
diagnosed by experienced neurologists specialized in motor
neuron disease, using revised El Escorial criteria [26]. CSF and
plasma samples were collected at the same office visit every four to
six months from 44 ALS patients (2–8 draws), and either once or
twice (1.5–2 years apart) from 35 non-neurologic healthy controls
(HC) and 25 neurologic disease controls (DC). Our total
enrollment of 104 patients provided adequate power for this study
as a pre-study power analysis using projected effect sizes based on
previous mass spectrometry findings [17] concluded that a total
enrollment of 96 patients was required to identify pairwise
differences between ALS patients and both HC and DC groups
for both measures of cystatin C. We did not control for potential
confounding variables such as socioeconomic status, nutrition,
environmental exposures, etc. between diagnostic groups. The
median time from symptom onset to first draw for ALS patients
was 468 days. Clinical parameters used to monitor ALS disease
progression included the rate of change in the revised ALS
functional rating scale (ALSFRS-R), manual muscle strength tests
(MMT), and forced vital capacity (FVC) [27,28,29].
The disease control group included six patients with multiple
sclerosis, one with bilateral facial palsies, one with neurosarcoi-
dosis, one with viral encephalitis, one with CNS lymphoma, one
with brain metastases, one with pseudotumor cerebri, one with a
seizure disorder, one with complicated migraine, one with
paresthesis and possible myelopathy, one with a probable
conversion disorder, and nine with neurologic diseases that can
clinically resemble ALS at presentation. This ALS-mimic disease
subgroup included two patients with primary lateral sclerosis
(PLS), two with chronic inflammatory demyelinating polyneurop-
athy (CIDP), two with progressive muscular atrophy, one with
spinocerebellar ataxia, one with small fiber neuropathy, and one
with idiopathic sensorimotor polyneuropathy. CSF samples were
obtained by lumbar puncture, immediately centrifuged at 450 g
for five minutes at 4uC to remove cells and debris, aliquoted, and
then frozen at 280uC. Intravenous blood samples were collected
in EDTA containing tubes, inverted to mix, and centrifuged at
1,733 g for 10 min at 4uC. The plasma was decanted, aliquoted,
and frozen at 280uC. CSF and plasma were aliquoted into small
volumes for single use in experiments in order to eliminate any
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freeze/thaw effects. Samples of either biofluid were thawed on ice
immediately prior to use.
Cystatin C ELISA
CSF and plasma samples from individual patients were assigned
to random 96-well plate positions, and evaluated in duplicate wells
for each ELISA. All samples were independently assayed at least
twice. For all experiments, we used a human cystatin C sandwich
ELISA kit (Biovendor, Candler, NC), according to the manufac-
turer’s instructions. Briefly, diluted CSF and plasma samples
(1:2000 and 1:400, respectively in dilution buffer) were applied to
antibody pre-coated ELISA plates for 30 min with gentle
agitation. The wells were washed thoroughly and then the
secondary antibody conjugate solution was applied for 30 min
with gentle agitation. After a second wash, the 3,39,5,59
Tetramethylbenzidine substrate solution (Biovendor, Candler,
NC) was applied for 10 min, color development was stopped with
an acidic stop solution, and the optical density was measured at
450 nm using a plate reader. Total protein concentrations for each
sample were calculated using a BCA protein assay (Pierce),
according to the manufacturer’s instructions.
Statistics
Data Processing. For each ELISA plate, a standard curve was
generated by plotting the logarithm of the cystatin C concentration
against the logit log of the adjusted optical density (divided by a
constant to produce a data range between zero and one, as required
for the logit logarithm function). This procedure produced a linear
standard curve, which was then used to calculate sample cystatin C
concentration from sample optical density. The data points were
averaged to determine the absolute cystatin C concentration, or
‘‘total cystatin C,’’ for each sample. Sample cystatin C
concentrations were normalized to the sample total protein
concentration to determine the percent of total biofluid protein
accounted for by cystatin C, or ‘‘percent cystatin C.’’
Assessment of Diagnostic Biomarker Utility. For the
analyses of diagnostic utility, we included only the initial sample
collected from each patient, representing the time point closest to
symptom onset. Differences between group and subgroup means
were identified using the SPSS generalized linear model, with
diagnosis and sex as factors in the model and age at draw as a
covariate. This model was subsequently used to calculate and
compare the estimated marginal group means, in order to
determine which pairwise differences among the levels of each
factor were responsible for the significant main effects.
Assessment of Longitudinal Change in Cystatin C. The
relationship between first-draw cystatin C levels and the length of
time from symptom onset was assessed by linear regression using
GraphPad Prism 5.0 software (GraphPad Software Inc, La Jolla,
CA). For this analysis, the ‘‘time from symptom onset’’ data were
transformed by the natural logarithm (Ln) in order to achieve
normality as required by the selected statistical test.
The effect of time on longitudinal cystatin C levels in ALS
patients with multiple biofluid draws was assessed with SPSS
software, using the general linear model for repeated measures.
The model was applied for all patients combined and for patient
subgroups sorted by progression speed. Fast progressors were
defined as patients exhibiting above average rates of ALSFRS
decline (median: 0.77 units/month [30]) or MMT decline (mean:
drop of 1%/month [29]), and slow progressors were defined as
patients exhibiting smaller than average longitudinal decreases in
both of these clinical progression measures.
The longitudinal relationship between cystatin C levels and clinical
disease progression in individual patients was assessed by nonpara-
metric correlation analysis (GraphPad Prism 5.0). The Spearman’s
rank correlation coefficient (r) was calculated and the permutation test
was applied to determine if r was significantly different from zero.
Assessment of Prognostic Biomarker Utility. The
relationship between first-draw cystatin C levels and post-draw
survival time (for deceased patients only) was assessed by Spearman
correlation analysis (GraphPad Prism 5.0). The prognostic utility of
CSF cystatin C was further explored by generating Kaplan-Meier
survival curves for patients falling above or below several cut-off
values of cystatin C. SPSS software was used to calculate the p-
values for differential survival time by three different methods: the
Log Rank (Mantel-Cox) test, the Breslow (Generalized Wilcoxon)
test, and the Tarone-Ware test. For all statistical analyses in this
study, the significance level was set at p,0.05.
Supporting Information
Figure S1 Correlation of ELISA-based cystatin C levels and
SELDI-TOF-MS 13.3 kDa mass peak intensity levels by Spearman
correlation analysis. Both total (A) and percent (B) cystatin C ELISA
measurements correlated to the 13.3 kDa cystatin C mass peak.
(TIF)
Figure S2 Correlation analysis for cystatin C levels in CSF and
plasma. There was no correlation between total cystatin C
concentrations (A) (r = 0.055; p = 0.626) or percent cystatin C
levels (B) (r = -0.076; p = 0.501) between CSF and plasma.
(TIF)
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